The Bradley group is currently involved in a multidisciplinary project called IMPACT (Implantable Microsystems for Personalised Anti-Cancer Therapy) led by Professor Alan Murray (University’s School of Engineering). The whole team consists of engineers, chemists, veterinary scientists, social scientists and human cancer specialists working together.

The project is aimed to the development of a small, wireless, inductively powered sensor that when implanted into a cancer will allow a patient’s tumour biology to be monitored continuously (measuring changes in hypoxia, pH) following radiotherapy. The chemistry strand is focused on the generation of electrochemical sensors for cancer biomarkers that can be miniaturised and integrated onto the implantable silicon based chip system.

The Chemistry strand of IMPACT has developed cancer biomarker biosensors for proteases and optimised them for:

1) Stability with a tripod anchor (Staderini, 2018)

2) Choice of redox tag (González-Fernández, 2016)

This research has shown that functional sensors have been validated for biomarkers such as cathepsins and human neutrophil elastase, capable of performance in complex medium such as human blood (González-Fernández, 2018)